New York State Common Retirement Fund’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $54.7K | Buy |
+5,600
| New | +$48.6K | ﹤0.01% | 2974 |
|
|
2024
Q3 | – | Sell |
-64
| Closed | -$829 | – | 3278 |
|
|
2024
Q2 | $829 | Sell |
64
-1,346
| -95% | -$22.3K | ﹤0.01% | 3296 |
|
|
2024
Q1 | $31.9K | Buy |
1,410
+118
| +9% | +$2.07K | ﹤0.01% | 3078 |
|
|
2023
Q4 | $16.8K | Sell |
1,292
-19
| -1% | -$256 | ﹤0.01% | 3166 |
|
|
2023
Q3 | $26.3K | Buy |
1,311
+47
| +4% | +$1.05K | ﹤0.01% | 3154 |
|
|
2023
Q2 | $33.9K | Sell |
1,264
-8
| -0.6% | -$345 | ﹤0.01% | 3194 |
|
|
2023
Q1 | $74.2K | Sell |
1,272
-2,000
| -61% | -$98.7K | ﹤0.01% | 2895 |
|
|
2022
Q4 | $167K | Sell |
3,272
-1,222
| -27% | -$84.7K | ﹤0.01% | 2799 |
|
|
2022
Q3 | $368K | Buy |
4,494
+1,236
| +38% | +$92.3K | ﹤0.01% | 2493 |
|
|
2022
Q2 | $220K | Sell |
3,258
-237
| -7% | -$21.7K | ﹤0.01% | 2757 |
|
|
2022
Q1 | $386K | Buy |
3,495
+655
| +23% | +$81.6K | ﹤0.01% | 2513 |
|
|
2021
Q4 | $274K | Sell |
2,840
-11
| -0.4% | -$1.1K | ﹤0.01% | 2753 |
|
|
2021
Q3 | $249K | Sell |
2,851
-1,102
| -28% | -$114K | ﹤0.01% | 2831 |
|
|
2021
Q2 | $612K | Sell |
3,953
-1,039
| -21% | -$151K | ﹤0.01% | 2487 |
|
|
2021
Q1 | $788K | Sell |
4,992
-366
| -7% | -$77.1K | ﹤0.01% | 2226 |
|
|
2020
Q4 | $1.24M | Hold |
5,358
| – | – | ﹤0.01% | 1941 |
|
|
2020
Q3 | $1.17M | Sell |
5,358
-429
| -7% | -$105K | ﹤0.01% | 1832 |
|
|
2020
Q2 | $1.64M | Buy |
5,787
+1,725
| +42% | +$510K | ﹤0.01% | 1614 |
|
|
2020
Q1 | $1.17M | Hold |
4,062
| – | – | ﹤0.01% | 1655 |
|
|
2019
Q4 | $1.17M | Buy |
4,062
+122
| +3% | +$26.5K | ﹤0.01% | 1881 |
|
|
2019
Q3 | $569K | Buy |
3,940
+973
| +33% | +$132K | ﹤0.01% | 2264 |
|
|
2019
Q2 | $267K | Hold |
2,967
| – | – | ﹤0.01% | 2678 |
|
|
2019
Q1 | $260K | Hold |
2,967
| – | – | ﹤0.01% | 2598 |
|
|
2018
Q4 | $417K | Sell |
2,967
-626
| -17% | -$106K | ﹤0.01% | 2366 |
|
|
2018
Q3 | $918K | Hold |
3,593
| – | – | ﹤0.01% | 2137 |
|
|
2018
Q2 | $916K | Buy |
3,593
+1,080
| +43% | +$267K | ﹤0.01% | 2147 |
|
|
2018
Q1 | $506K | Buy |
2,513
+480
| +24% | +$95.7K | ﹤0.01% | 2347 |
|
|
2017
Q4 | $293K | Hold |
2,033
| – | – | ﹤0.01% | 2594 |
|
|
2017
Q3 | $335K | Buy |
2,033
+153
| +8% | +$21.9K | ﹤0.01% | 2555 |
|
|
2017
Q2 | $255K | Buy |
1,880
+473
| +34% | +$70K | ﹤0.01% | 2723 |
|
|
2017
Q1 | $271K | Sell |
1,407
-555
| -28% | -$89.1K | ﹤0.01% | 2650 |
|
|
2016
Q4 | $277K | Sell |
1,962
-484
| -20% | -$65.4K | ﹤0.01% | 2650 |
|
|
2016
Q3 | $357K | Sell |
2,446
-18
| -0.7% | -$2.16K | ﹤0.01% | 2491 |
|
|
2016
Q2 | $248K | Sell |
2,464
-2,951
| -54% | -$383K | ﹤0.01% | 2628 |
|
|
2016
Q1 | $725K | Hold |
5,415
| – | – | ﹤0.01% | 2098 |
|
|
2015
Q4 | $1.08M | Hold |
5,415
| – | – | ﹤0.01% | 1926 |
|
|
2015
Q3 | $855K | Buy |
5,415
+602
| +13% | +$161K | ﹤0.01% | 2036 |
|
|
2015
Q2 | $1.96M | Buy |
+4,813
| New | +$2.08M | ﹤0.01% | 1863 |
|
Other funds holding KPTI
RCM
ACA
CCM
APM
New York State Common Retirement Fund's KPTI Position: Q2 2026 in Review
New York State Common Retirement Fund opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 5,600 shares worth $54.7K. The stake represents ﹤0.01% of the portfolio and ranks #2974 among its holdings. This is a return to the name: New York State Common Retirement Fund previously reported a position in KPTI as recently as Q2 2024.
New York State Common Retirement Fund first reported a position in KPTI in Q2 2015 and has held it in 38 quarters since. The position peaked at $1.96M in Q2 2015. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.
- New York State Common Retirement Fund held 5,600 shares of Karyopharm Therapeutics worth $54.7K as of Q2 2026.
- Karyopharm Therapeutics was a new New York State Common Retirement Fund position in Q2 2026.
- Karyopharm Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2974 holding.
- New York State Common Retirement Fund first reported a position in Karyopharm Therapeutics in Q2 2015 and has held it in 38 quarters since.
- New York State Common Retirement Fund's Karyopharm Therapeutics position peaked at $1.96M in Q2 2015.
- 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.